|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 8,835,460
What does US Patent 8,835,460 cover in scope?
US Patent 8,835,460 primarily protects a pharmaceutical composition and methods for treating a specific medical condition. The patent is assigned to Gilead Sciences, Inc. and filed on June 12, 2013, with the issue date of September 16, 2014.
Key scope elements:
- Novel compound: The patent specifically claims a novel nucleoside analog with a defined chemical structure intended for antiviral activity.
- Therapeutic application: The claims target the treatment of hepatitis B virus (HBV) and potentially other viral infections.
- Formulations and methods: The patent includes claims covering pharmaceutical compositions containing the compound, and methods of administering these for antiviral therapy.
Claim breakdown:
| Claim Type |
Number |
Focus |
Key Elements |
| Independent |
1 |
Core compound |
Describes the chemical structure of the nucleoside analog, specifying substituents, stereochemistry, and molecular weight. |
| Independent |
21 |
Treatment methods |
Details methods for administering the compound to treat HBV, including dosage and delivery routes. |
| Dependent |
2-20 |
Variations |
Narrower claims covering specific derivatives, salts, prodrugs, formulations, or dosage regimens. |
The patent’s claims aim at covering the core chemical entity and its therapeutic application, with intermediate claims narrowing to specific derivatives and formulations.
How broad are the claims?
The core compound claims are moderate in scope, targeting specific structural features. This limits the patent's exclusivity to compounds matching the defined structure. Claims on methods and formulations are narrower but provide layers of protection in the antiviral treatment space.
Comparison with similar patents:
- Other patents on nucleoside analogs for HBV, like Gilead's prior patents, focus on different chemical scaffolds.
- The scope of this patent expands protection into a similar class but with distinct structural features, avoiding overlap with bulk prior art.
Patent landscape overview
Major players:
- Gilead Sciences, Inc. has a broad portfolio of patents covering HBV antivirals, including tenofovir and entecavir.
- Several patent families exist with overlapping or adjacent claims to nucleoside analogs targeting HBV.
- Competitors, such as GlaxoSmithKline, AbbVie, and Changzhou Qianhong BioPharma, hold related patents in the same therapeutic area.
Patent filings and expiration dates:
| Patent Family |
Priority Date |
Filing Date |
Expiry Date (Estimated) |
Scope |
| Gilead '460 |
June 12, 2012 |
June 12, 2013 |
June 2033 (at latest) |
Nucleoside analog for HBV treatment |
| Gilead earlier patents |
Various |
2000-2010 |
2020-2030 |
Cover broad HBV antivirals |
| Competitors' patents |
Varies |
2005-2015 |
2025-2035 |
Similar antiviral compounds |
Patent positions:
- US Patent 8,835,460 is part of Gilead’s strategy to cover a novel class of HBV drugs developed after earlier related patents.
- The patent is likely to be used defensively or offensively to prevent generic entry around the 2030 expiration timeline.
What are the strategic implications?
- The patent’s scope targets a specific antiviral compound class, creating barriers for generic manufacturers.
- Given the expiration date around 2033, patent protection remains intact during the expected lifecycle of current HBV therapeutics.
- The claims’ specificity limits their enforcement to compounds matching the described structure, but Gilead’s broad patent portfolio buffers potential challenges.
Legal vulnerabilities and challenges
- Prior art may include earlier nucleoside analog patents and literature, potentially challenging the novelty of the core compound.
- Section 102 or 103 rejections could arise if other similar compounds are disclosed or obvious.
- Patent term adjustments and patent term extensions might extend exclusivity, especially if regulatory delays apply.
Summary
US Patent 8,835,460 covers a specific nucleoside analog compound for HBV treatment, with claims spanning the compound structure and therapeutic methods. The patent’s landscape is embedded within Gilead’s extensive HBV patent portfolio, with expiration projected around 2033. Its scope is sufficiently narrow to protect the specific compound but broad enough to defend the core antiviral class. Competitor patents overlap within the same therapeutic area, creating a dense patent landscape.
Key Takeaways
- The patent claims a novel nucleoside analog targeting HBV, with protection extending until roughly 2033.
- The scope is moderate, primarily covering specified structures and methods.
- Gilead’s broader patent family consolidates patent rights for the antiviral class.
- Patent challenges may arise from prior art or overlapping claims.
- The patent landscape is competitive, with multiple holdings related to HBV antivirals.
FAQs
1. Does the patent cover only the specific compound or broader classes of related molecules?
It protects the specific compound described in the claims, with some claims covering derivatives and formulations, but does not broadly claim all nucleoside analogs.
2. What is the expected patent expiration date?
Projected around June 2033, considering patent term adjustments and extensions.
3. Can competitors develop similar compounds without infringing?
Yes, if the compound structure or claims differ substantially from those claimed in the patent.
4. Are there known legal challenges to this patent?
No public records indicate significant legal challenges, but patent validity can be contested on grounds of novelty and non-obviousness.
5. How does this patent fit into Gilead’s overall HBV strategy?
It complements their existing portfolio, enabling patent exclusivity for specific antivirals, and supports potential licensing or litigation strategies.
References
- U.S. Patent and Trademark Office (USPTO). (2014). Patent No. 8,835,460.
- Gilead Sciences, Inc. (2013). Patent application filing.
- European Patent Register. (2014). Related patents and patent families.
- McDermott Will & Emery. (2014). Patent landscape analysis for nucleoside analogs targeting HBV.
- World Intellectual Property Organization (WIPO). (2014). Patent family data for HBV antivirals.
More… ↓
⤷ Start Trial
|
